Global Pharma and Life Sciences deals insights: Q2 2019
Following a busy start to the year, PLS deal activity remained strong through the second quarter
A total of seven megadeals were announced in the first half of 2019, including four in the second quarter. This brings us just one shy of the total number of megadeals in all of 2018. Second quarter deal activity was highlighted by AbbVie's announced acquisition of Allergan for $86.0B. Aside from this megadeal for the Ireland-based Allergan, each of the top ten largest transactions during the quarter had targets based in the U.S.
Download Global pharma & life sciences deals insights: Q2 2019
Related documents:
- Global pharma & life sciences deals insights: Q1 2019
- Global pharma & life sciences deals insights: Year-end 2018
- Pharmaceuticals and Life Sciences Deals Insights: Q3 2018
- Pharmaceuticals and Life Sciences Deals Insights: Q2 2018
- Pharmaceuticals and Life Sciences Deals Insights: Q1 2018
- Pharmaceuticals and Life Sciences Deals Insights: Year-end 2017
- Pharmaceuticals and Life Sciences Deals Insights: Q3 2017
- Pharmaceuticals and Life Sciences Deals Insights: Q2 2017
Deal value declines slightly, while volume increases vs Q1 2019
While down slightly from Q1 2019, Q2 2019 is still the second highest deal value the sector has seen in the past eight quarters.
Deal volume is up from Q1 2019, and the number of deals was the second highest the sector has seen in the last two years.
The sector saw four megadeals this quarter, totaling approximately $110B in value, compared to Q1 2018 which had 3 megadeals with a combined total of $129B in value.
Large spikes in deal value during Q2 2018, Q1 2019, and Q2 2019 were driven by significant megadeal activity.
